An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patients With Cushing's Disease

Trial Profile

An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patients With Cushing's Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Pituitary ACTH hypersecretion
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top